共 7 条
[1]
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Pietras RJ,Pegram MD,Finn RS,et al. Oncegene . 1998
[2]
The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization ( FISH) in the Herceptin pivotal trials. Mass RD,Sanders C,Charlene K,et al. Proceedings of the American Society of Clinical Oncology . 2000
[3]
Inhibitory effects of combinations of HER-2 neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Pegram M,Hsu S,Lewis G,et al. Oncegene . 1999
[4]
Multinational study of the efficacy and safety of humanized anti -HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Cobleigh MA,Vogel CL,Tripathy D,et al. Journal of Clinical Oncology . 1999
[5]
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti -p185HER2 neu monoclonal antibody plus cisplatin in patients with HER2 neu-over expressing metastatic breast cancer refractory to chemotherapy treatment. Pegram MD,Lipton A,Hayes DF,et al. Journal of Clinical Oncology . 1998
[6]
Overall survival( OS ) advantage to Herceptin ( H) in HER2-overexpressing( HER2 +) metastatic breast cancer ( MBC). Norton L,Slamon D,Leyland Jones B,et al. Proceedings of the American Society of Clinical Oncology . 1999
[7]
Recombinant humanized anti -HER2 antibody (Herceptina) enhances the antitumor activity of paclitaxel and doxorubicin against HER2 neu overexpressing human breast cancer xenografts. Baselga J,Norton L,Albanell J,et al. Cancer Research . 1998